《生病时的医疗费用：关于全球制药业的真实情况》（有声书）

English | October 07, 2021 | ASIN: B099X8HDC6 | M4B@128 kbps | 13h 51m | 770 MB

The pharmaceutical industry is broken. From the American hedge fund manager who hiked the price of an AIDS pill from $17.50 to $750 overnight to the children's cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system that was designed to drive innovation and patient care has been relentlessly distorted to drive up profits.

Medicines have become nothing more than financial assets. The focus of drug research, how drugs are priced and who has access to them, is now dictated by shareholder value, not the good of the public. Drug companies fixated on ever-higher profits are being fined for bribing doctors and striking secret price-gouging deals, while patients desperate for life-saving medicines are driven to the black market in search of drugs that national health services can't afford.

Sick Money argues that the way medicines are developed and paid for is no longer working. Unless we take action, we risk a dramatic decline in the pace of drug development and a future in which medicines are only available to the highest bidder. In this book, investigative journalist Billy Kenber offers a diagnosis of an industry in crisis and a prescription for how we can fight back.

医药行业已经崩坏。从那位将艾滋病药物的价格从17.50美元一口气提高到750美元的美国对冲基金经理，到有意让儿童癌症药物在西班牙仓库过期的那个案例，这种失调的现象随处可见。一个原本旨在促进创新和患者护理的系统如今却被无情扭曲以追求利润。 药品已经变成纯粹的金融资产。制药研究的重点、药品定价的方式以及谁能够获得它们，现在都被股东价值所左右，而不是公共利益。专注于获取更高利润的制药公司正因贿赂医生和签订秘密价格垄断协议而受到罚款，与此同时，那些迫切需要救命药物的患者却不得不走向黑市以寻找国家卫生服务负担不起的药物。 《病钱》一书指出药品的研发及支付方式已经不再有效。如果不采取行动，我们将面临药品研发速度大幅放缓的风险，并最终导致只有最高出价者才能获得药品的情况。在本书中，调查记者Billy Kenber提出了一个针对陷入危机行业的诊断和应对之策。

---

Download from free file storage

 Download from nitroflare.com  Download from ddownload.com

---

我要反馈

---

本站不对文件进行储存，仅提供文件链接，请自行下载，本站不对文件内容负责，请自行判断文件是否安全，如发现文件有侵权行为，请联系管理员删除。